StartX

Daily

StartX accelerator launching new Stanford-area lab with QB3

Stanford-backed accelerator StartX has partnered with QB3 to open a new life sciences laboratory called, aptly, “StartX-QB3 Labs.” It’s the first research space that’s both close to Stanford and is focused on that bench-to-bedside approach of bringing entrepreneurs from academia to industry. The new, 2,000-square-foot space will be able to house up to 20 life science […]

sponsored content

A Deep-dive Into Specialty Pharma

A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.

Hospitals

New fund from Stanford & Stanford Hospital will invest in entrepreneurial graduates

Stanford University produces more alumni entrepreneurs than any other university, and now it’s created its first fund to invest directly in those early-stage companies emerging from the university community. Stanford has established a three-year partnership with Stanford Hospital & Clinics and StartX, an accelerator for students, faculty, alumni and staff, under which the institutions will […]

Health IT

Using data to find new drug-disease matches wins startup NuMedii its first pharma deal

Pairing existing drugs with new disease applications, using not wet labs but computers, has landed a Stanford startup its first contract with a pharmaceutical company. NuMedii has signed its first product-focused deal with specialty pharmaceutical company Aptalis Pharma, which develops therapies for cystic fibrosis and gastrointestinal disorders. The big data startup will use its predictive […]